Cisplatin micelle - CSPC Zhongqi Pharmaceutical Technology
Alternative Names: Cisplatin micelle injectionLatest Information Update: 28 Dec 2023
At a glance
- Originator CSPC ZhongQi Pharmaceutical Technology
- Class Antineoplastics; Platinum complexes; Small molecules
- Mechanism of Action DNA cross linking agents; DNA synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 Dec 2023 No recent reports of development identified for preclinical development in Solid-tumours in China (Parenteral, Injection)
- 21 Apr 2022 CSPC Zhongqi Pharmaceutical Technology plans to launch cisplatin micelle injection in China
- 21 Apr 2022 NMPA grants clinical trial approval for cisplatin micelle injection in Solid tumours in China